General Information of Drug (ID: DMB9IPR)

Drug Name
RS-504393 Drug Info
Synonyms
300816-15-3; RS 504393; 6-Methyl-1'-(2-(5-methyl-2-phenyloxazol-4-yl)ethyl)spiro[benzo[d][1,3]oxazine-4,4'-piperidin]-2(1H)-one; RS-504393; RS504393; CHEMBL134074; 6-Methyl-1'-(2-(5-methyl-2-phenyloxazol-4-yl)ethyl)spiro-[benzo[d][1,3]oxazine-4,4'-piperidin]-2(1H)-one; 6-Methyl-1'-[2-(5-methyl-2-phenyl-4-oxazolyl)ethyl]spiro[4H-3,1-benzoxazine-4,4'-piperidin]-2(1H)-one; ACMC-20a25e; GTPL781; SCHEMBL9972645; CTK4G4374; CHEBI:93525; DTXSID20433290; MolPort-021-804-998; BCPP000086; HMS3269M19; BCP02713; ZINC13527116; ABP000463
Indication
Disease Entry ICD 11 Status REF
Chronic obstructive pulmonary disease CA22 Preclinical [1]
Cross-matching ID
PubChem CID
9953769
ChEBI ID
CHEBI:93525
CAS Number
CAS 300816-15-3
TTD Drug ID
DMB9IPR

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Clinical Trial Drug(s)
Discontinued Drug(s)
Preclinical Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Bindarit DMS2GA1 Nephritis GB40 Phase 3 [4]
Carlumab DMAUN15 Pulmonary fibrosis CB03.4 Phase 2 [5]
NOX-E36 DMHG3UR Diabetic complication 5A2Y Phase 2 [6]
CNTO888 DMUBP0V Solid tumour/cancer 2A00-2F9Z Phase 1 [7]
ABN-912 DMADKHB Asthma CA23 Discontinued in Phase 1 [8]
MCP-1 DMYEFKH Rheumatoid arthritis FA20 Preclinical [9]
⏷ Show the Full List of 6 Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Cenicriviroc DM4V8WF Human immunodeficiency virus infection 1C62 Phase 2 [10]
MLN1202 DM24SOL Metastatic cancer 2D50-2E2Z Phase 2 [9]
BMS-813160 DMKY638 Diabetic nephropathy GB61.Z Phase 2 [11]
CCX-140 DMJ9XCO Diabetic nephropathy GB61.Z Phase 2 [12]
AZD-2423 DMF34UY Chronic obstructive pulmonary disease CA22 Phase 2 [13]
CCX872 DMPVAUT Pancreatic tumour 2C10 Phase 2 [14]
MK-0812 DMRT8K4 Multiple sclerosis 8A40 Phase 2 [15]
Aminoguanidine DMJQDUC Diabetic retinopathy 9B71.0 Phase 1 [16]
TAK-202 DMVYEFZ Melanoma 2C30 Phase 1 [17]
OPL-CCL2-LPM DM3HOUX Arthritis FA20 Phase 1 [18]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
C-C chemokine receptor type 2 (CCR2) TTFZYTO CCR2_HUMAN Antagonist [2]
Monocyte chemotactic and activating factor (CCL2) TTNAY0P CCL2_HUMAN Inhibitor [3]

References

1 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 781).
2 Beneficial or detrimental effects of carotenoids contained in food: cell culture models. Mini Rev Med Chem. 2007 Nov;7(11):1120-8.
3 Privileged structures: a useful concept for the rational design of new lead drug candidates. Mini Rev Med Chem. 2007 Nov;7(11):1108-19.
4 Bindarit: an anti-inflammatory small molecule that modulates the NF B pathway. Cell Cycle. 2012 Jan 1;11(1):159-69.
5 Carlumab, an anti-C-C chemokine ligand 2 monoclonal antibody, in combination with four chemotherapy regimens for the treatment of patients with solid tumors: an open-label, multicenter phase 1b study. Target Oncol. 2015 Mar;10(1):111-23.
6 Crystal structure of a mirror-image L-RNA aptamer (Spiegelmer) in complex with the natural L-protein target CCL2. Nat Commun. 2015 Apr 22;6:6923.
7 CCL2 as an important mediator of prostate cancer growth in vivo through the regulation of macrophage infiltration. Neoplasia. 2007 Jul;9(7):556-62.
8 A randomized controlled trial with an anti-CCL2 (anti-monocyte chemotactic protein 1) monoclonal antibody in patients with rheumatoid arthritis. Arthritis Rheum. 2006 Aug;54(8):2387-92.
9 Emerging drugs for the treatment of chronic obstructive pulmonary disease. Expert Opin Emerg Drugs. 2006 May;11(2):275-91.
10 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
11 A dual CCR2/CCR5 chemokine antagonist, BMS-813160. Expert Opin Ther Pat. 2011 Dec;21(12):1919-24.
12 Present and future in the treatment of diabetic kidney disease. J Diabetes Res. 2015;2015:801348.
13 CA patent application no. 841416, Method of selecting therapeutic indications.
14 Therapeutic use of a clinical stage CCR2 inhibitor, CCX872, in obesity-associated steatohepatitis. The Lancet Volume 383, Supplement 1, 26 February 2014, Pages S78.
15 Assessment of chemokine receptor function on monocytes in whole blood: In vitro and ex vivo evaluations of a CCR2 antagonist. J Immunol Methods. 2010 Jan 31;352(1-2):101-10.
16 Incyte Announces Second Quarter 2005 Financial Results; Reports Positive Phase IIb Results for Reverset in Treatment-Experienced HIV Patients. Incyte Corporation. 2005.
17 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
18 Selective CCR2-targeted macrophage depletion ameliorates experimental mesangioproliferative glomerulonephritis. Clin Exp Immunol. 2009 February; 155(2): 295-303.